Adocia Investor Relations Material

Adocia SA is a biotechnology company focused on the development of innovative therapies for the treatment of diabetes and other metabolic diseases. The company specializes in creating advanced formulations of already approved therapeutic proteins, aiming to improve their efficacy and patient experience. Adocia's technology platforms are designed to optimize the delivery and performance of these treatments, particularly in the field of insulin therapy. The company is headquartered in Lyon, France, and its shares are listed on the Euronext Paris exchange.